Evaluation of efficacy and toxicity 	of Interleukin 2 given subcutaneously in the treatment of disseminated renal cancer and malignant melanoma

Beata Wiczyńska; Marek Pawlicki; Marek Ziobro; Tomasz Zemełka

eISSN: 1897-4309
ISSN: 1428-2526

Contemporary Oncology/Współczesna Onkologia

Current issue Archive Manuscripts accepted About the journal Supplements Addendum Special Issues Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

3/2001
vol. 5

Send email

Copy url:

abstract:

Evaluation of efficacy and toxicity of Interleukin 2 given subcutaneously in the treatment of disseminated renal cancer and malignant melanoma

Beata Wiczyńska

,

Marek Pawlicki

,

Marek Ziobro

,

Tomasz Zemełka

Współcz Onkol (2001) vol. 5, 3 (90-94)

Online publish date: 2003/07/14

View full text Get citation

Thirty patients with malignant melanoma or renal cancer were treated with Interleukin 2 given subcutaneously in Medical Oncology Department, Cancer Centre, Krakow-Branch in the period from January 1998 to June 1999. In the group of renal cancer two (11,1%) patients achieved a partial remission and 11 (61,1%) a stabilization of the disease lasting 10 and 8.8 month with survival time 12 and 12.2 month, respectively. Among patients with disseminated malignant melanoma two (16,7%) patients achieved complete remission and one patient (8,3%) partial remission of the disease lasted 10 and 12 month, respectively. Mean survival time was 16 and 19 month, respectively.

Therapy was well tolerated, however, in 10% patients cardiovascular toxicity (hypotension) and renal toxicity (BUN and creatinine level elevation) were observed.

keywords:

Evaluation of efficacy and toxicity of Interleukin 2 given subcutaneously in the treatment of disseminated renal cancer and malignant melanoma

Beata Wiczyńska , Marek Pawlicki , Marek Ziobro , Tomasz Zemełka

interleukine, renal cancer, malignant melanoma

Beata Wiczyńska

,

Marek Pawlicki

,

Marek Ziobro

,

Tomasz Zemełka